Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/Regeneron's melanoma drug trial misses key goal, triggering analyst downgrades.

REGN

$665.13

+$9.02 +1.37%

Regeneron's melanoma drug trial misses key goal, triggering analyst downgrades.

Market News

18 May 2026

Proactive Investors

View Source

Bearish

Regeneron Pharmaceuticals' phase 3 trial for its melanoma drug fianlimab, combined with cemiplimab, failed to meet the primary goal of significantly improving progression-free survival compared to Merck's Keytruda. Although the combination extended median progression-free survival by 5.1 months, it narrowly missed statistical significance, raising doubts about its effectiveness. This setback led to analyst downgrades and follows earlier disappointing trial results in lung cancer. A separate trial comparing fianlimab to a rival drug continues, but the recent failure raises concerns about the drug's commercial future.

More News (REGN)

Baird's international and global growth funds underperform MSCI benchmarks in Q2 2026.

In Q2 2026, Baird's Chautauqua International Growth Fund returned +10.39%, trailing the MSCI ACWI ex-U.S. Index's +14.49%. Key detractors included Alibaba and Lululemon, while Recruit and ASML contributed positively. The Global Growth Fund also lagge...

Market News

Neutral

2 days ago